News

Survival shorter in young gastric cancer patients


 

AT A MEETING ON GASTROINTESTINAL CANCERS SPONSORED BY THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Patients with gastric adenocarcinoma who were diagnosed before age 40 years died significantly sooner than did older patients, based on the results of a single-center, retrospective study of 520 cases.

Patients diagnosed before age 40 survived a median of 5 months after diagnosis; 24% were alive at 1 year. Older patients survived a median of 8 months, and 39% were alive at 1 year, reported Dr. Bryan Goldner and his associates.

Surgical exploration was often futile in the younger patients, said Dr. Goldner of Harbor-UCLA Medical Center in Torrance, Calif. Surgery removed all tumors with histologically free margins (R0 resection) in 33% of younger patients, compared with 60% of older patients, he reported in a poster presentation at a meeting on gastrointestinal cancers sponsored by the American Society of Clinical Oncology.

Recent reports in the medical literature suggest that younger patients with gastric adenocarcinoma are more likely to be diagnosed with node-positive and metastatic disease. One retrospective study of 350 patients found that younger patients had more aggressive gastric adenocarcinomas and died sooner than older patients (Arch. Surg. 2009;144:506-10).

A separate retrospective study of 33,236 U.S. patients found that younger patients presented with more advanced gastric adenocarcinoma but had better survival outcomes than older patients when stratified by disease stage (Ann. Surg. Oncol. 2011;18:2800-7).

Gastric cancer might not be suspected in younger patients, which could result in young patients going undiagnosed until their cancers are more advanced, Dr. Goldner suggested.

The meeting was cosponsored by ASCO, the American Gastroenterological Association Institute, the American Society for Radiation Oncology, and the Society of Surgical Oncology.

Dr. Goldner reported having no financial disclosures.

s.boschert@elsevier.com

On Twitter @sherryboschert

Recommended Reading

Obesity, diabetes fuel liver disease epidemic
MDedge Family Medicine
States spend little tobacco revenue on prevention
MDedge Family Medicine
Cancer survival still lower for African Americans
MDedge Family Medicine
Folic acid supplements have no effect on cancer rates
MDedge Family Medicine
Job stress not linked with cancer risk
MDedge Family Medicine
FDA approves pomalidomide for advanced multiple myeloma
MDedge Family Medicine
Bevacizumab plus chemo extends survival in metastatic cervical cancer
MDedge Family Medicine
Gene profiling predicted responses to colorectal, pancreatic cancer treatment
MDedge Family Medicine
Screen asymptomatic siblings of CRC patients
MDedge Family Medicine
Breast-conserving therapy improved survival over mastectomy
MDedge Family Medicine